ORIC Oric Pharmaceuticals |
$13.17 -3.4% |
+0.1%
 |
Rinzimetostat
patients with metastatic castration-resistant prostate cancer
|
|
10/23/2026 - Preclinical Data
ORIC Pharmaceuticals, Inc. announced preclinical and translational data from an ePoster presentatio… Full Summary
|
ALNY Alnylam Pharmaceuticals |
$224.03 -1.4% |
-12.5%
 |
ALN-HTT02
in Huntington’s Disease
|
Phase 1b
|
10/23/2026 - Results
Alnylam Pharmaceuticals, Inc. today reported positive initial Phase 1b clinical trial results for AL… Full Summary
|
PHAT Phathom Pharmaceuticals |
$5.74 -18.1% |
-21.4%
 |
VOQUEZNA
or the relief of heartburn associated with Non-Erosive GERD in adults
|
|
10/23/2026 - Provided Update
Phathom Pharmaceuticals, Inc announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR)… Full Summary
|
IDYA IDEAYA Biosciences |
$34.71 -3.9% |
-5.4%
 |
IDE849
In Solid Tumors
|
|
10/23/2026 - Results
IDEAYA Biosciences, Inc announced updated clinical results that show promising anti-tumor activity a… Full Summary
|
TNGX Tango Therapeutics |
$23.34 -16.4% |
-6.3%
 |
vopimetostat
patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC).
|
Phase 1/2
|
10/23/2026 - Results
Tango Therapeutics, Inc. announced promising results from its ongoing Phase 1/2 study of vopimetost… Full Summary
|
ZLAB Zai Lab |
$24.03 +9.0% |
-3.8%
 |
ZL-1310
treatment for extensive-stage small cell lung cancer (ES-SCLC).
|
|
10/23/2026 - Data
Zai Lab Limited today shared the first data from a global Phase 1b clinical trial evaluating zocilur… Full Summary
|
BLRX BioLineRx |
$2.04 -1.0% |
-21.5%
 |
GLIX1
treatment of recurrent and progressive glioblastoma
|
|
10/23/2026 - Data Presentation
BioLineRx Ltd. announced today that the companies presented data at the 2026 European Society for Me… Full Summary
|
AARD Aardvark Therapeutics |
$1.39 -64.8% |
-72.5%
 |
ARD-101
for Prader-Willi Syndrome
|
Phase 3
|
10/23/2026 - Efficacy Data
Aardvark Therapeutics, Inc. today reported exploratory efficacy data from its previously terminated… Full Summary
|
RVMD Revolution Medicines |
$186.99 -0.4% |
-8.8%
 |
daraxonrasib
For previously treated metastatic PDAC in patients with KRAS G12 mutations.
|
Phase 3
|
10/23/2026 - Analysis
Revolution Medicines, Inc announced that exploratory subgroup analyses from the Phase 3 RASolute 302… Full Summary
|
BMY Bristol Myers Squibb |
$61.58 -2.3% |
-2.0%
 |
iza-bren
For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
|
|
10/23/2026 - Results
SystImmune, Inc and Bristol Myers Squibb announced that SystImmune’s parent company Sichuan Bioki… Full Summary
|
HUMA Humacyte |
$0.44 +5.4% |
-21.9%
 |
V012
acellular tissue engineered vessel (ATEV) in arteriovenous
|
Phase 3
|
10/23/2026 - Positive Results
Humacyte, Inc. announced that positive interim results from the V012 Phase 3 clinical trial of the a… Full Summary
|
MGNX MacroGenics |
$2.25 -38.0% |
-39.8%
 |
MGC026
in patients with advanced solid tumors
|
Phase 1
|
10/23/2026 - Interim Data
MacroGenics, Inc. announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3… Full Summary
|
CELC Celcuity |
$65.25 -0.5% |
-17.9%
 |
Gedatolisib
HR+ / HER2- Metastatic Breast Cancer
|
Phase 1b/2
|
10/23/2026 - Results
Celcuity Inc announced updated clinical results from the Phase 1b/2 study evaluating gedatolisib in … Full Summary
|
GMAB Genmab A/S |
$43.79 +9.5% |
+24.0%
 |
Rina-S
In Heavily Pretreated Patients with Ovarian and Endometrial Cancers
|
Phase 3
|
10/23/2026 - Top-line results
Genmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabar… Full Summary
|
IONS Ionis Pharmaceuticals |
$42.93 -2.2% |
-3.5%
 |
sefaxersen
in IgA nephropathy (IgAN)
|
|
10/23/2026 - Oral presentation
Ionis Pharmaceuticals, Inc announced today late-breaking oral presentation data from the ongoing Ph… Full Summary
|
VRTX Vertex Pharmaceuticals |
$523.93 -2.1% |
-0.4%
 |
povetacicept
in IgA nephropathy
|
|
10/23/2026 - Publication
Vertex Pharmaceuticals Incorporated announced the publication of Phase 3 RAINIER results for pove… Full Summary
|
ABBV AbbVie |
$285.66 +0.2% |
+8.0%
 |
SKYRIZI (risankizumab-rzaa) PsA
Active Psoriatic Arthritis
|
|
10/23/2026 - FDA approved
AbbVie announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction re… Full Summary
|
CLYM Climb Bio |
$10.19 -3.3% |
-12.6%
 |
CLYM116
for IgAN
|
|
10/23/2026 - Additional data
Climb Bio, Inc. announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-… Full Summary
|
CLYM Climb Bio |
$10.19 -3.3% |
-12.6%
 |
CLYM116
for IgAN
|
Target date: H1 2027
|
10/23/2026 - Initial Data
Climb Bio, Inc. announced that the NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in… Full Summary
|
ARDX Ardelyx |
$3.08 -3.8% |
-9.9%
 |
tenapanor
Control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis
|
|
10/23/2026 - Results
Ardelyx, Inc. announced results from a real-world analysis presented at the American Society of Neph… Full Summary
|
CGTX Cognition Therapeutics |
$0.72 +2.6% |
-23.2%
 |
CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.
|
Phase 3
|
10/22/2026 - Provided Update
Cognition Therapeutics, a clinical-stage company developing product candidates that treat neurodegen… Full Summary
|
TFX Teleflex |
$136.50 -0.1% |
+11.5%
 |
Freesolve™ RMS
to Target Lesion Failure (TLF) ratea at 12 months
|
Breakthrough Device
|
10/22/2026 - Designation Grant
Teleflex Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted Breakt… Full Summary
|
GILD Gilead Sciences |
$156.04 -0.7% |
+3.4%
 |
Trodelvy (sacituzumab govitecan-hziy)
Metastatic urothelial cancer (UC)
|
|
10/22/2026 - evaluation
BioNTech SE announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc… Full Summary
|
MDT Medtronic |
$95.48 -1.1% |
+7.9%
 |
PulseSelect
To treat atrial fibrillation
|
|
10/22/2026 - Results
- Medtronic plc announced positive real-world registry results for the Affera™ Mapping and Ablatio… Full Summary
|
ABUS Arbutus Biopharma |
$4.20 -0.2% |
-13.4%
 |
AB-101
Oral PD-L1 inhibitor
|
|
10/22/2026 - Clinical hold Removed
Arbutus Biopharma announced that the Company was notified by the U.S. Food and Drug Administration … Full Summary
|
ABOS Acumen Pharmaceuticals |
$1.98 -3.9% |
-11.6%
 |
Sabirnetug
for Early Alzheimer's Disease
|
|
10/22/2026 - Poster Presentation
Acumen Pharmaceuticals, will present three key poster presentations at the upcoming 19th Annual Clin… Full Summary
|
CRBP Corbus Pharmaceuticals |
$4.05 -1.9% |
-43.3%
 |
CRB-913
For Obesity
|
|
10/22/2026 - Late-Breaking Data
Corbus Pharmaceuticals announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study w… Full Summary
|
SCYX SCYNEXIS |
$3.79 -0.5% |
-13.7%
 |
SCY-247
For systemic fungal diseases
|
Phase 1
|
10/22/2026 - Top-line results
SCYNEXIS, Inc. announced topline results from its Phase 1 single ascending dose (SAD) and multiple a… Full Summary
|
DMAC DiaMedica Therapeutics |
$8.72 +1.0% |
+9.8%
 |
DM199
Chronic Kidney Disease Stage II or III
|
Phase 2/3
|
10/22/2026 - Enrollment Update
DiaMedica Therapeutics Inc announced that the 200th patient has been enrolled in its pivotal Phase… Full Summary
|
GILD Gilead Sciences |
$156.04 -0.7% |
+3.4%
 |
seladelpar
For the Treatment of Primary Biliary Cholangitis Including Pruritus
|
|
10/22/2026 - Data Presentation
Gilead Sciences, Inc will present new clinical and real-world evidence across primary biliary chol… Full Summary
|
DMAC DiaMedica Therapeutics |
$8.72 +1.0% |
+9.8%
 |
DM199
Chronic Kidney Disease Stage II or III
|
Target date: Q1 2027
|
10/22/2026 - Analysis
DiaMedica Therapeutics Inc announced that the Interim Analysis Results Expected in Q1 2027 Full Summary
|
ABBV AbbVie |
$285.66 +0.2% |
+8.0%
 |
lutikizumab
in Patients with Hidradenitis Suppurativa
|
Phase 3
|
10/22/2026 - Top-line results
AbbVie announced positive topline results from the Phase 3 INTREPID study evaluating the safety and … Full Summary
|
IFRX InflaRx |
$1.56 +2.0% |
-17.5%
 |
Izicopan
small molecule inhibitor of the C5a receptor (C5aR)
|
|
10/22/2026 - Presentation
InflaRx N.V announced the presentation of new pre-clinical data on izicopan in renal disease models … Full Summary
|
VOR Vor Biopharma |
$18.26 -3.6% |
-1.4%
 |
telitacicept
Sjögren's Disease
|
Phase 3
|
10/22/2026 - Results
Vor Bio announced final two-year results from the Phase 3 TELIGAN trial evaluating telitacicept in a… Full Summary
|
AARD Aardvark Therapeutics |
$1.39 -64.8% |
-72.5%
 |
ARD-101
for Prader-Willi Syndrome
|
|
10/22/2026 - Lifted Clinical Hold
Aardvark Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted th… Full Summary
|
MRNA Moderna |
$200.10 -1.2% |
+0.6%
 |
mRNA-4157/V940 (KEYTRUDA)
Provide an additive benefit and enhance T cell-mediated destruction of tumor cells.
|
|
10/22/2026 - Provided Update
Merck and Moderna, Inc announced detailed positive recurrence-free survival (RFS) and distant met… Full Summary
|
MRK Merck & Co., Inc. |
$145.25 -1.4% |
-2.4%
 |
mRNA-4157/V940 (KEYTRUDA)
Provide an additive benefit and enhance T cell-mediated destruction of tumor cells.
|
|
10/22/2026 - Provided Update
Merck and Moderna, Inc announced detailed positive recurrence-free survival (RFS) and distant met… Full Summary
|
PSNL Personalis |
$15.85 +0.2% |
-3.7%
 |
NeXT Personal
in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
|
|
10/21/2026 - Oral presentation
Personalis, Inc announced that two oral presentations and two poster presentations featuring its NeX… Full Summary
|
SMMT Summit Therapeutics |
$15.47 -0.5% |
-0.9%
 |
Ivonescimab
For Lung cancer
|
|
10/21/2026 - Clinical Trial
Summit Therapeutics Inc. announced a clinical trial collaboration with the ECOG-ACRIN Cancer Resear… Full Summary
|
SMMT Summit Therapeutics |
$15.47 -0.5% |
-0.9%
 |
Ivonescimab
For Lung cancer
|
Target date: Q4 2026
|
10/21/2026 - Clinical Trial
Summit Therapeutics Inc. announced Clinical Trial Site Activations in the United States Expected … Full Summary
|
MRK Merck & Co., Inc. |
$145.25 -1.4% |
-2.4%
 |
KEYTRUDA®(pembrolizumab)
For the treatment of patients with locally advanced or metastatic urothelial carcinoma
|
EC Approval
|
10/21/2026 - Approved
Merck Receives European Commission Approval For KEYTRUDA In Combination With Padcev For Adults With … Full Summary
|
IRD Opus Genetics |
$3.47 -9.2% |
-27.1%
 |
OPGx-RDH12
for Inherited Childhood Blindness
|
IND
|
10/21/2026 - FDA Clearance
Opus Genetics, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared its Inves… Full Summary
|
IMUX Immunic |
$7.41 +2.6% |
-20.7%
 |
IMU-838
In Patients with Post COVID Syndrome (RAPID_REVIVE)."
|
|
10/21/2026 - New Data
- Immunic, Inc. announced that new clinical, biomarker, and preclinical data for its lead investigat… Full Summary
|
JBIO Jade Biosciences |
$14.59 -2.1% |
+1.2%
 |
JADE101
For the treatment of IgA nephropathy (IgAN)
|
|
10/21/2026 - Provided Update
Jade Biosciences, Inc announced that three posters related to JADE101, a novel, ultra-high affinit… Full Summary
|
JBIO Jade Biosciences |
$14.59 -2.1% |
+1.2%
 |
JADE101
For the treatment of IgA nephropathy (IgAN)
|
Target date: Q2 2027
|
10/21/2026 - Highlights
Jade Biosciences, Inc. announced that the JUNIPER Phase 2 Trial-in-Progress poster highlights ongoi… Full Summary
|
BCRX BioCryst Pharmaceuticals |
$7.65 -1.7% |
-10.9%
 |
ORLADEYO (berotralstat)
Hereditary angioedema (HAE)
|
supplemental New Drug Application (sNDA)
|
10/21/2026 - FDA approved
BioCryst Pharmaceuticals, Inc announced the U.S. Food and Drug Administration (FDA) has approved it… Full Summary
|
INMB INmune Bio |
$1.46 -5.2% |
-28.1%
 |
Ebstrocel
rare and severe genetic skin
|
|
10/21/2026 - Application Submitted
INmune Bio Inc. announced that it has submitted its final pre-Marketing Authorisation Application (p… Full Summary
|
INMB INmune Bio |
$1.46 -5.2% |
-28.1%
 |
Ebstrocel
rare and severe genetic skin
|
Target date: February 1, 2027
|
10/21/2026 - Marketing authorization
INmune Bio Inc. announced that the Full MAA submission targeted for early February 2027 Full Summary
|
INMB INmune Bio |
$1.46 -5.2% |
-28.1%
 |
Ebstrocel
rare and severe genetic skin
|
BLA Target date: Q2 2027
|
10/21/2026 - Provided Update
INmune Bio Inc. announced that the U.S. BLA expected to be submitted in Q2, 2027 Full Summary
|
STRO Sutro Biopharma |
$9.33 -9.3% |
-41.6%
 |
STRO-006
In Patients With Range Of Solid Tumors
|
Phase 1
|
10/21/2026 - Dose Update
Sutro Biopharma, Inc. announced that the first patient has been dosed in its Phase 1 trial of STRO… Full Summary
|
STRO Sutro Biopharma |
$9.33 -9.3% |
-41.6%
 |
STRO-006
In Patients With Range Of Solid Tumors
|
Target date: H2 2027
|
10/21/2026 - Initial Data
Sutro Biopharma, Inc announced that the Initial clinical data expected in the second half of 2027 Full Summary
|
ACHV Achieve Life Sciences |
$6.49 -0.2% |
-13.9%
 |
cytisinicline
For the treatment of nicotine dependence
|
|
10/21/2026 - Results
Achieve Life Sciences, Inc. announced positive 52-week efficacy results from its long-term, open-lab… Full Summary
|
LXRX Lexicon Pharmaceuticals |
$1.42 -4.7% |
-20.9%
 |
sotagliflozin
INPEFA™ (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1).
|
|
10/21/2026 - Findings Update
Lexicon Pharmaceuticals, Inc today highlighted findings from two newly reported preclinical studie… Full Summary
|
BEAT HeartBeam |
$0.39 -1.2% |
+9.3%
 |
HEADSTART-ACS
in detecting acute coronary syndrome
|
|
10/21/2026 - Provided Update
HeartBeam, Inc announced that the HEADSTART-ACS study, conducted at the National Cardiovascular Cen… Full Summary
|
BEAT HeartBeam |
$0.39 -1.2% |
+9.3%
 |
HEADSTART-ACS
in detecting acute coronary syndrome
|
|
10/21/2026 - Provided Update
HeartBeam, Inc. announced that the study enrolled 486 patients with data analysis underway and the… Full Summary
|
SCYX SCYNEXIS |
$3.79 -0.5% |
-13.7%
 |
SCY-247
For systemic fungal diseases
|
|
10/21/2026 - Provided Update
SCYNEXIS, Inc. announces that SCY-247, its second-generation triterpenoid (fungerp) antifungal candi… Full Summary
|
CRDF Cardiff Oncology |
$0.91 -2.2% |
-26.8%
 |
onvansertib
in Chronic Myelomonocytic Leukemia
|
Orphan Drug
|
10/21/2026 - Designation Grant
Cardiff Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orph… Full Summary
|
RAPP Rapport Therapeutics |
$25.93 -2.3% |
-23.5%
 |
RAP-219
For CNS Disorders
|
Phase 2
|
10/20/2026 - Top-line results
Rapport Therapeutics, Inc. announced positive topline results from its Phase 2 trial of RAP-219 i… Full Summary
|
QNRX Quoin Pharmaceuticals |
$4.07 +1.4% |
-36.7%
 |
QRX003
Nethertons Syndrome
|
|
10/20/2026 - Publication
Quoin Pharmaceuticals Ltd. announced the publication of a peer-reviewed manuscript titled "An Invest… Full Summary
|
QNRX Quoin Pharmaceuticals |
$4.07 +1.4% |
-36.7%
 |
QRX003
Nethertons Syndrome
|
Target date: Q2 2027
|
10/20/2026 - Top-line data
Quoin Pharmaceuticals Ltd. announced that the Topline Data Expected in Q2 2027 Full Summary
|
ODTX Odyssey Therapeutics |
$19.60 +2.7% |
-4.4%
 |
OD-001
in Ulcerative Colitis
|
|
10/20/2026 - Results
Odyssey Therapeutics, Inc. announced results from the completed induction period of its Phase 2a cl… Full Summary
|
TEVA Teva Pharmaceutical Industries |
$39.39 -2.0% |
+0.6%
 |
duvakitug
for the treatment of moderate-to-severe inflammatory bowel disease (IBD).
|
Phase 2b
|
10/20/2026 - Positive Data
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd and Sanofi announced ne… Full Summary
|
RVMD Revolution Medicines |
$186.99 -0.4% |
-8.8%
 |
Zoldonrasib
for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC
|
Phase 3
|
10/20/2026 - Provided Update
Revolution Medicines, Inc announced that it has begun treating patients in RASolve 308, a global Ph… Full Summary
|
BIVI BioVie |
$1.24 -3.1% |
-22.7%
 |
Bezisterim
For Parkinson's Disease Patients
|
Phase 2
|
10/20/2026 - Presentation
BioVie Inc. announced the presentation of results from the Phase 2 SUNRISE-PD clinical trial evaluat… Full Summary
|
RCUS Arcus Biosciences |
$18.54 -4.2% |
-25.6%
 |
casdatifan
In patients with ccRCC
|
|
10/20/2026 - New Data
Arcus Biosciences, Inc announced new data at an investor event in New York City from the ARC-20 pla… Full Summary
|
NBIX Neurocrine Biosciences |
$142.70 -0.4% |
+3.1%
 |
NBI-1117567
for the potential treatment of neurological and neuropsychiatric conditions.
|
Phase 2
|
10/20/2026 - Initiation
Neurocrine Biosciences, announced the initiation of its Phase 2 clinical study of investigational c… Full Summary
|
AMGN Amgen |
$439.26 -1.8% |
+5.9%
 |
TEZSPIRE
in chronic obstructive pulmonary disease
|
Phase 3
|
10/20/2026 - Results
AstraZeneca announced Full results from the positive Phase III CROSSING trial showed that AstraZenec… Full Summary
|
IONS Ionis Pharmaceuticals |
$42.93 -2.2% |
-3.5%
 |
bepirovirsen
treatment of chronic hepatitis B (CHB)
|
|
10/20/2026 - FDA approved
Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved … Full Summary
|
AAPG Ascentage Pharma Group International |
$15.40 +3.2% |
+3.6%
 |
lisaftoclax
In Venetoclax-Refractory Patients
|
Breakthrough Therapy
|
10/20/2026 - Designation Grant
Ascentage Pharma Group announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhib… Full Summary
|
ABBV AbbVie |
$285.66 +0.2% |
+8.0%
 |
ABBV-466
in Moderate to Severe Crohn's Disease
|
|
10/19/2026 - Provided Update
AbbVie announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p1… Full Summary
|
LLY Eli Lilly and Company |
$1,275.50 -2.4% |
+7.7%
 |
mirikizumab-mrkz
For Crohn's disease
|
Phase 3
|
10/19/2026 - Results
Eli Lilly and Company announced positive late-breaking one-year results from the Phase 3 SHINE-2 stu… Full Summary
|
TAK Takeda Pharmaceutical |
$20.26 -0.5% |
+7.5%
 |
vedolizumab
approved in intravenous (IV) and subcutaneous (SC) formulations
|
|
10/19/2026 - New Data
Takeda announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous … Full Summary
|
IDYA IDEAYA Biosciences |
$34.71 -3.9% |
-5.4%
 |
Darovasertib
Non-metastatic uveal melanoma (UM)
|
|
10/19/2026 - Updated data
IDEAYA Biosciences, Inc announced updated clinical data from three ongoing studies evaluating darov… Full Summary
|
BNTX BioNTech |
$88.11 -1.7% |
-10.6%
 |
BNT327
In small-cell lung cancer and in triple-negative breast cancer
|
|
10/19/2026 - Clinical Data
BioNTech SE will present new clinical data from its late-stage oncology pipeline with 16 abstracts s… Full Summary
|
BMY Bristol Myers Squibb |
$61.58 -2.3% |
-2.0%
 |
BNT327
In small-cell lung cancer and in triple-negative breast cancer
|
|
10/19/2026 - Clinical Data
BioNTech SE will present new clinical data from its late-stage oncology pipeline with 16 abstracts s… Full Summary
|
UTHR United Therapeutics |
$587.50 +0.5% |
+23.6%
 |
treprostinil SMI
in PH-COPD.
|
|
10/19/2026 - FDA Clearance
United Therapeutics Corporation announced that the U.S. Food and Drug Administration (FDA) has gra… Full Summary
|
INSM Insmed |
$93.39 -1.8% |
-20.7%
 |
BRINSUPRI
Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
|
|
10/19/2026 - Provided Update
Insmed Incorporated announced the commercial launch in Japan of BRINSUPRI® Tablets 25 mg (brensocati… Full Summary
|
SMMT Summit Therapeutics |
$15.47 -0.5% |
-0.9%
 |
Ivonescimab
For Lung cancer
|
Phase 2
|
10/19/2026 - Initiation
Summit Therapeutics Inc. announced the initiation and opening of clinical trial sites of a multireg… Full Summary
|
MANE Veradermics |
$139.53 +0.8% |
+19.1%
 |
VDPHL01
Patient Experiences With Pattern Hair Loss
|
|
10/19/2026 - Top-line results
Veradermics, Incorporated announced positive topline results from Part A of its randomized, double-… Full Summary
|
TNXP Tonix Pharmaceuticals |
$5.17 +0.8% |
-47.6%
 |
Tonmya
For the management of fibromyalgia.
|
|
10/19/2026 - Provided Update
Tonix Pharmaceuticals Holding Corp. announced a poster examining the effects of TONMYA® (cyclobenzap… Full Summary
|
PBLS Parabilis Medicines |
$24.44 -9.2% |
-21.7%
 |
Zolucatetide
key driver of a range of cancers and tumor types.
|
|
10/19/2026 - Clinical Data
Parabilis Medicines announced that updated clinical data for zolucatetide in patients with desmoid … Full Summary
|
EYPT Eyepoint Pharmaceuticals |
$0.40 -5.5% |
-88.8%
 |
DURAVYU
In patients with non-proliferative diabetic retinopathy (NPDR).
|
Phase 3
|
10/19/2026 - Positive Results
EyePoint, Inc. announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of DU… Full Summary
|
XNCR Xencor |
$25.18 -2.6% |
+5.8%
 |
XmAb819
patients with clear cell renal cell carcinoma
|
Phase 1
|
10/19/2026 - Provided Update
Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the t… Full Summary
|
CYTK Cytokinetics |
$61.23 -1.8% |
-5.3%
 |
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
|
|
10/19/2026 - Provided Update
Cytokinetics, announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (a… Full Summary
|
BIIB Biogen |
$250.69 -1.2% |
+10.1%
 |
EMPAVELI
investigational anti-CD38 monoclonal antibody.
|
|
10/19/2026 - Data Presentation
Biogen Inc. will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations … Full Summary
|
CRMD CorMedix |
$7.85 -3.1% |
|
REZZAYO
in the prevention of Candida, Aspergillus, and Pneumocystis infection in patients undergoing allogeneic blood and marrow transplantation (BMT).
|
supplemental New Drug Application (sNDA)
|
10/19/2026 - sNDA Filing
CorMedix Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for f… Full Summary
|
MIST Milestone Pharmaceuticals |
$0.65 -7.8% |
-17.8%
 |
Etripamil
For Treatment in Paroxysmal Supraventricular Tachycardia
|
|
10/19/2026 - Data Presentation
Milestone® Pharmaceuticals Inc announced that data and program updates for CARDAMYST® (etripamil) … Full Summary
|
URGN Urogen Pharma |
$34.49 -1.9% |
-16.6%
 |
UGN-103
For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
NDA
|
10/19/2026 - FDA Accepted
UroGen Pharma Ltd. announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Appl… Full Summary
|
URGN Urogen Pharma |
$34.49 -1.9% |
-16.6%
 |
UGN-103
For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
NDA Target date: June 14, 2027
|
10/19/2026 - PDUFA Date
UroGen Pharma Ltd. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) ta… Full Summary
|
ALT Altimmune |
$2.12 -2.3% |
-30.7%
 |
pemvidutide
for the treatment of obesity and MASH
|
|
10/19/2026 - New Data
Altimmune, Inc. announced that new clinical and preclinical data on pemvidutide will be presented a… Full Summary
|
INVA Innoviva |
$20.66 -1.9% |
-0.4%
 |
ZEVTERA
For the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).
|
|
10/19/2026 - Abstract Presentation
Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. announced today it will prese… Full Summary
|
BIVI BioVie |
$1.24 -3.1% |
-22.7%
 |
Bezisterim
For Parkinson's Disease Patients
|
Phase 2
|
10/19/2026 - Presentation
BioVie Inc announced the presentation of results from the Phase 2 ADDRESS-LC study (NCT06847191) eva… Full Summary
|
ARGX argenex |
$873.71 -0.2% |
-8.9%
 |
ALKIVIA
In Idiopathic Inflammatory Myopathies
|
Phase 3
|
10/19/2026 - New Data
argenx SE announced that new data from the Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod … Full Summary
|
JNJ Johnson & Johnson |
$264.13 -1.3% |
-2.7%
 |
Guselkumab
For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
|
Phase 3
|
10/19/2026 - Results
Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA® (gusel… Full Summary
|
SGP Spyglass Pharma |
$28.48 +0.9% |
+5.2%
 |
Bimatoprost
in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract.
|
|
10/19/2026 - Results
SpyGlass Pharma, Inc. announced positive 4-year first-in-human (FIH) trial results for the Bimatopro… Full Summary
|
RIGL Rigel Pharmaceuticals |
$48.13 -1.5% |
-0.1%
 |
Gavreto (Pralsetinib)
Rearranged during transfection (RET) fusion-positive advanced Non-small cell lung cancer (NSCLC)
|
|
10/19/2026 - Analysis
Rigel Pharmaceuticals, Inc. announced analysis of the pooled efficacy and safety data from two clin… Full Summary
|
ARGX argenex |
$873.71 -0.2% |
-8.9%
 |
VYVGART Hytrulo
Injection for Subcutaneous Use in Generalized Myasthenia Gravis
|
Phase 3
|
10/19/2026 - New Data
argenx SE announced that new data from the Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod … Full Summary
|
DRTS Alpha Tau Medical |
$13.16 +2.0% |
-9.5%
 |
Alpha DaRT
Prostate cancer
|
Investigational Device Exemption
|
10/19/2026 - FDA approved
Alpha Tau Medical Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved an I… Full Summary
|
XBIT XBiotech |
$1.93 -2.0% |
-11.1%
 |
XB2001 (1-BETTER)
Pancreatic Cancer
|
Phase 2
|
10/19/2026 - Positive Results
XBiotech Inc. announced positive final efficacy results from the randomized Phase II portion of the… Full Summary
|
BCDA BioCardia |
$0.92 -0.8% |
-12.3%
 |
Helix Transendocardial Delivery Catheter
intramyocardial therapeutic and diagnostic agent delivery.
|
|
10/19/2026 - FDA Accepted
BioCardia, Inc. announced the FDA has accepted its pre-submission package for marketing clearance o… Full Summary
|